|
| Press Releases |
|
 |
|
| Wednesday, April 14, 2021 |
|
|
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting |
| Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401). more info >> |
|
| Monday, April 12, 2021 |
|
|
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021 |
| Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021. more info >> |
|
| Wednesday, March 31, 2021 |
|
|
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries |
| KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei. more info >> |
|
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan |
| Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
| Tuesday, March 30, 2021 |
|
|
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab |
| Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate, in combination with anti-PD-1 therapy pembrolizumab. more info >> |
|
| Friday, March 26, 2021 |
|
|
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 |
| Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel, the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ. more info >> |
|
| Tuesday, March 23, 2021 |
|
|
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan |
| Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma. more info >> |
|
| Monday, March 22, 2021 |
|
|
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan |
| Eisai Co., Ltd. announced today that, as part of one strategic investment towards the realization of its medium-term business plan "EWAY2025", it has conducted the groundbreaking ceremony for the construction of a new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan. more info >> |
|
|
Eisai Awarded The New Diversity Management Selection 100 |
| Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister's Award of the New Diversity Management Selection 100 by METI. This marks the first time to be awarded ever since Eisai was included in the New Diversity Management Selection 100 Program. more info >> |
|
| Wednesday, March 17, 2021 |
|
|
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders |
| Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer's disease (AD) which modulate immune competence in neurons and glia cells. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
MHI Thermal Systems Air-Conditioners for the Australian Market Recognized with Prestigious Awards
Oct 17, 2025 23:37 JST
|
|
|
SEKISUI CHEMICAL, Fujitsu, and SAP Japan announce comprehensive modernization of management platform to drive data-driven approach
Oct 17, 2025 23:00 JST
|
|
|
Blockpass and RWA Inc. Partner to Effect Verifiable Trust in Real World Asset & DePIN Tokenization 
Oct 17, 2025 17:00 HKT/SGT
|
|
|
TransNusa to Launch Bali - Singapore Scheduled Flight on November 17
Oct 17, 2025 16:58 JST
|
|
|
MHIEC Receives Contract for Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kanazawa
Oct 16, 2025 23:57 JST
|
|
|
Canada Backs Advanced Tokenization and Distributed Federated Learning Research with Over $3 Million in Funding
Oct 16, 2025 22:45 HKT/SGT
|
|
|
Overview of Honda Exhibits at Japan Mobility Show 2025
Oct 16, 2025 23:20 JST
|
|
|
DENSO to Exhibit at JAPAN MOBILITY SHOW 2025
Oct 16, 2025 22:53 JST
|
|
|
Fujitsu and IISc launch joint research on advanced AI technologies to accelerate new material development and resolve societal challenges
Oct 16, 2025 21:55 JST
|
|
|
Kincora Appoints Kerry Stevenson and Michelle Borromeo to the Advisory Board
Oct 16, 2025 20:09 HKT/SGT
|
|
|
45th Electronics Fair and electronicAsia attract some 60,000 buyers
Oct 16, 2025 19:06 HKT/SGT
|
|
|
Radisson Expands Ongoing Step-Out Drill Program at O'Brien to 140,000 Metres
Oct 16, 2025 18:39 HKT/SGT
|
|
|
How DPC Dash-Domino's Pizza China Is Capturing China's Pizza Market
Oct 16, 2025 14:30 HKT/SGT
|
|
|
SERES Passes HKEX Listing Hearing - First 'A+H' Dual-Listed Premium NEV Maker Poised for Hong Kong Debut
Oct 16, 2025 14:28 HKT/SGT
|
|
|
Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models
Oct 16, 2025 13:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
